Lipid-Based Nanocarriers in Renal RNA Therapy

• Published in: Biomedicines Vol. 10; no. 2; p. 283
• Main Authors: Su, Chi-Ting, See, Daniel H W, Huang, Jenq-Wen
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 26.01.2022; MDPI
• Subjects: Adaptability; Cancer therapies; Clinical trials; Coronaviruses; COVID-19; Diabetes; Drug delivery systems; Gene expression; Kidney diseases; Kinases; Lipids; Lymphocytes; MicroRNAs; miRNA; nanoparticle; Nanotechnology; Pathogenesis; Pathophysiology; Proteins; Public health; renal disease; Review; Ribonucleic acid; RNA; RNA therapy; RNA-mediated interference; RNAi; siRNA; Therapeutic applications; Vaccines; RNAi; lipid nanocarrier; RNA therapy; miRNA; nanoparticle; siRNA; renal disease
• ISSN: 2227-9059; 2227-9059
• DOI: 10.3390/biomedicines10020283

Kidney disease is a multifactorial problem, with a growing prevalence and an increasing global burden. With the latest worldwide data suggesting that chronic kidney disease (CKD) is the 12th leading cause of death, it is no surprise that CKD remains a public health problem that requires urgent attention. Multiple factors contribute to kidney disease, each with its own pathophysiology and pathogenesis. Furthermore, microRNAs (miRNAs) have been linked to several types of kidney diseases. As dysregulation of miRNAs is often seen in some diseases, there is potential in the exploitation of this for therapeutic applications. In addition, uptake of interference RNA has been shown to be rapid in kidneys making them a good candidate for RNA therapy. The latest advancements in RNA therapy and lipid-based nanocarriers have enhanced the effectiveness and efficiency of RNA-related drugs, thereby making RNA therapy a viable treatment option for renal disease. This is especially useful for renal diseases, for which a suitable treatment is not yet available. Moreover, the high adaptability of RNA therapy combined with the low risk of lipid-based nanocarriers make for an attractive treatment choice. Currently, there are only a small number of RNA-based drugs related to renal parenchymal disease, most of which are in different stages of clinical trials. We propose the use of miRNAs or short interfering RNAs coupled with a lipid-based nanocarrier as a delivery vehicle for managing renal disease.